Table 3.

Comparison of mortality in presence or absence of TACE during and after discontinuation of sorafenib administration

	Sorafenib (+) TACE (+) vs. TACE (-)		Sorafenib (-) TACE (+) vs. TACE (-)
Subgroups		Subgroups
Group I (n = 52)	14/21 vs. 28/31 p = 0.002*	Group I (n = 38)	6/10 vs. 24/28 p = 0.001*
Group II (n = 58)	13/21 vs. 23/37 p = 0.595	Group II (n = 40)	4/10 vs. 23/30 p = 0.034*
Group III (n = 46)	12/15 vs. 24/31 p = 0.074	Group III (n = 31)	3/6 vs. 20/25 p = 0.647
HCC-total Patients (N = 156)	39/57 vs. 75/99 p = 0.002*	HCC-total Patients (N = 109)	13/26 vs. 67/83 p = 0.001*

Abbreviations: Group I always accepted 800 mg/day; Group II initially accepted 800 mg/day tapering to 400 mg/day owing to adverse events; Group III always accepted 400 mg/day. TACE transarterial chemoembolization

*A P-value below 0.05 is considered statistically significant